Table 1.

Patient and disease characteristics

n (% of total 161 patients)
Age
 Median (range)62 (23–88)
 Patients <65 years94 (58%)
Sex
 Male124 (77%)
 Female37 (23%)
ECOG PS
 0—1123 (76.4%)
 ≥238 (23.6%)
Primary site
 Esophagus/GEJ85 (53%)
 Gastric76 (47%)
Grade
 Moderately differentiated51 (31.7%)
 Poorly differentiated106 (65.8%)
 Unknown4 (2.5%)
HER-2 status
 Positive18 (11.2%)
 Negative139 (86.3%)
 Unknown4 (2.5%)
MMR/MSI status
 MMR-deficient/MSI15 (9.3%)
 MMR intact/MSS106 (65.8%)
 Unknown40 (24.8%)
PD-L1 status
 PD-L1–positive45 (28%)
 PD-L1–negative24 (14.9%)
 Unknown92 (57.1%)
Number of prior regimens
 0–2112 (69.6%)
 ≥3 (range 3–6)49 (30.4%)
Previous therapies
 Fluoropyrimidine137 (85%)
 Platinum135 (84%)
 Taxane96 (60%)
 Ramucirumab65 (40%)
 Irinotecan51 (32%)
 Trastuzumab21 (13%)
 Gemcitabine9 (6%)
 Anthracycline5 (3%)
 Other14 (9%)
Number of sites of disease at start of ICI
 1–2105 (65.2%)
 ≥356 (34.8%)
Type of ICI
 Single-agent anti–PD-1/PD-L1110 (68.3%)
 Combination anti–CTLA-4 plus anti–PD-1/PD-L151 (31.7%)